A recent study on breast cancer revealed that the injection of the fibulin-7 protein in an animal model with breast tumors delayed the reprogramming of tumor-associated macrophages (TAMs) mediated by the negative regulation of the STAT3 pathway, which suggests that fibulin-7 may become a potential anti-cancer therapeutic agent [133]. This evidence concerns the gene FBLN7 and breast cancer.